CHO Pharma, Inc. (TPEX:6586)
Taiwan · Delayed Price · Currency is TWD 115.50
-2.50 (-2.12%)
Aug 6, 2026, 9:08 AM CST
CHO Pharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -290.01 | -212.23 | -306.09 | -338.39 | -205.93 |
Depreciation & Amortization | 26.69 | 25.9 | 28.28 | 39.85 | 39.08 |
Asset Writedown & Restructuring Costs | - | - | 52.73 | - | 6 |
Stock-Based Compensation | 5.04 | -14.3 | -7.66 | 21.99 | -13.84 |
Other Operating Activities | -2.98 | -2.96 | -2 | -0.01 | 0 |
Change in Accounts Receivable | 0.75 | -0.75 | - | 0.06 | -0.06 |
Change in Accounts Payable | -12.68 | -2.52 | -52.68 | 38.24 | -16.47 |
Change in Unearned Revenue | 5.33 | - | - | - | - |
Change in Other Net Operating Assets | -11.71 | -10.52 | -3.71 | -11.24 | -2.26 |
Operating Cash Flow | -279.57 | -217.38 | -291.13 | -249.5 | -193.47 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -9.3 | -5.49 | -2 | -9.4 | -2.64 |
Sale (Purchase) of Intangibles | -2.4 | - | - | - | - |
Investment in Securities | 336.1 | 54.8 | -1,860 | - | - |
Other Investing Activities | -0.22 | 0.09 | 2.57 | 0.39 | -0.39 |
Investing Cash Flow | 324.19 | 49.4 | -1,859 | -9.01 | -3.03 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | -14.31 | -14.04 | -11.7 | -14.4 | -12.52 |
Net Debt Issued (Repaid) | -14.31 | -14.04 | -11.7 | -14.4 | -12.52 |
Issuance of Common Stock | - | - | 1,860 | 0.5 | 1.21 |
Financing Cash Flow | -14.31 | -14.04 | 1,849 | -13.9 | -11.31 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -0.03 | 0.04 | 0.05 | 0.09 | -0.6 |
Net Cash Flow | 30.28 | -181.98 | -301.87 | -272.33 | -208.41 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -288.87 | -222.87 | -293.13 | -258.9 | -196.11 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -20186.58% | -6225.53% | - | -431501.67% | -5493.25% |
Free Cash Flow Per Share | -1.35 | -1.04 | -1.53 | -1.41 | -1.07 |
Levered Free Cash Flow | -203.49 | -165.45 | -206.15 | -140.34 | -128.96 |
Unlevered Free Cash Flow | -203.24 | -165.02 | -206.1 | -140.15 | -128.6 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.41 | 0.68 | 0.08 | 0.3 | 0.58 |
Cash Income Tax Paid | 3.13 | 3.11 | 0.46 | 0.01 | - |
Change in Working Capital | -18.31 | -13.79 | -56.38 | 27.06 | -18.79 |